[
  {
    "table_index": 1,
    "headers": [],
    "rows": [
      [
        "End Note"
      ],
      [
        "Procite"
      ],
      [
        "Reference Manager"
      ]
    ],
    "row_count": 3,
    "column_count": 1
  },
  {
    "table_index": 2,
    "headers": [],
    "rows": [
      [
        "PSC",
        "Chronic, cholestatic liver disease likely of autoimmune origin characterized by inflammation and fibrosis of intrahepatic and/or extrahepatic bile ducts, leading to the formation of bile duct strictures, and frequently associated with IBD"
      ],
      [
        "Small‐duct PSC",
        "Less common variant of PSC that is characterized by typical cholestatic and histological features of PSC but with normal bile ducts on cholangiography"
      ],
      [
        "PSC–AIH overlap",
        "Concurrent diagnostic features of PSC and clinical, biochemical, and histological features of AIH"
      ],
      [
        "Secondary sclerosing cholangitis",
        "Biliary strictures due to identifiable causes that can result in secondary biliary cirrhosis"
      ],
      [
        "IgG4 sclerosing cholangitis",
        "Biliary strictures due to elevated IgG4‐positive plasma cells in tissue and serum IgG4 elevation frequently associated with pancreatic involvement"
      ],
      [
        "Dominant stricture",
        "A biliary stricture on ERCP with a diameter of ≤1.5 mm in the common bile duct or of ≤1 mm in the hepatic duct"
      ],
      [
        "High‐grade stricture",
        "A biliary stricture on MRI with cholangiopancreatography with >75% reduction in the common bile duct or hepatic ducts"
      ],
      [
        "Relevant stricture",
        "Any biliary stricture of the common bile duct or hepatic ducts associated with signs or symptoms of obstructive cholestasis and/or bacterial cholangitis"
      ]
    ],
    "row_count": 8,
    "column_count": 2
  },
  {
    "table_index": 3,
    "headers": [],
    "rows": [
      [
        "Infectious",
        "HIV‐related cholangiopathy Recurrent pyogenic cholangitis Cholangitis lenta or subacute nonsuppurative cholangitis Parasitic cholangiopathy • Hydatid cyst • Echinococcosis • Clonorchiasis and opisthorchiasis • Ascariasis • Fascioliasis • Schistosomiasis"
      ],
      [
        "Ischemic",
        "Critically ill patients Hereditary hemorrhagic telangiectasis Intra‐arterial chemotherapy Hepatic artery thrombosis"
      ],
      [
        "Malignant",
        "Cholangiocarcinoma Diffuse intrahepatic metastasis Langerhans cell histiocytosis Lymphoma"
      ],
      [
        "Autoimmune",
        "Eosinophilic cholangitis Hepatic inflammatory pseudotumor IgG4‐associated cholangitis Mast cell cholangiopathy Sarcoidosis"
      ],
      [
        "Anatomic",
        "Choledocholithiasis Intrahepatic lithiasis Cystic fibrosis liver disease Surgical biliary trauma Anastomotic stricture Portal hypertensive biliopathy Recurrent pancreatitis Sickle cell cholangiopathy Choledochal cyst"
      ],
      [
        "Drug‐induced",
        "Immunotherapy with checkpoint inhibitorsPembrolizumabNivolumabAtezolizumab"
      ]
    ],
    "row_count": 6,
    "column_count": 2
  },
  {
    "table_index": 4,
    "headers": [
      "",
      "Models"
    ],
    "rows": [
      [
        "Variables",
        "Age Bilirubin Albumin AST ALP Platelets PSC subtype (large‐duct or small‐duct)",
        "Age Bilirubin Albumin ALP Platelets Presence of extrahepatic biliary disease History of variceal hemorrhage",
        "Age Bilirubin Albumin AST ALP Platelets Hemoglobin Sodium Years since PSC diagnosis",
        "Bilirubin Albumin Platelets GGT Cholangiography (large‐duct or small‐duct involvement)"
      ],
      [
        "Endpoint",
        "LT or liver‐related death by 15 years",
        "Short term: death or LT by 2 years Long term: death or LT by 10 years",
        "Hepatic decompensation (ascites, variceal hemorrhage, encephalopathy) by 5 years",
        "Portal hypertensive complications, biliary complications, CCA, listing for LT, or death from liver disease by 5 years"
      ],
      [
        "Risk thresholdsa",
        "Lower risk: < 1.58 Higher risk: ≥ 1.58",
        "Lower risk: < 1.46 Higher risk: ≥ 1.46",
        "Lower risk: < 20% Higher risk: ≥ 20%",
        "Lower risk: 0–5 Higher risk: 6–11"
      ],
      [
        "Website",
        "https://sorted.co/psc‐calculator/",
        "http://www.uk‐psc.com/resources/the‐uk‐psc‐risk‐scores/",
        "rtools.mayo.edu/PRESTO_calculator/",
        "Scopeindex.net"
      ]
    ],
    "row_count": 4,
    "column_count": 2
  },
  {
    "table_index": 5,
    "headers": [
      "Vitamin",
      "Clinical symptoms",
      "Recommend daily doses (children)",
      "Recommend daily doses (adults)",
      "Comments"
    ],
    "rows": [
      [
        "Vitamin A",
        "Night blindness, xerophthalmia",
        "5000–10,000 IU daily",
        "1500–5000 IU daily",
        "5000–100,000 IU daily × 2 weeks",
        "1500–5000 IU daily",
        "Frequent monitoring to avoid hypervitaminosis A"
      ],
      [
        "Vitamin Dd",
        "Osteomalacia,aosteoporosis,bRickets,ctetany in children",
        "4000–8000 IU daily",
        "400–2000 IU daily",
        "Serum 25(OH)D < 12 ng/ml",
        ""
      ],
      [
        "50,000 IU weekly × 8 weeks",
        "800 IU daily",
        "May require higher doses or use of hydroxylated vitamin D metabolites"
      ],
      [
        "Serum 25(OH)D 12–20 ng/ml"
      ],
      [
        "800–1000 IU daily",
        "800–1000 IU daily"
      ],
      [
        "Serum 25(OH)D 20–30 ng/ml",
        ""
      ],
      [
        "600–800 IU daily",
        "600–800 IU daily",
        ""
      ],
      [
        "Vitamin E",
        "Neuropathy, ataxia, progressive neuromuscular disorder, hemolytic anemia",
        "100–200 mg daily",
        "15–25 mg daily",
        "200–2000 mg daily",
        "15 mg daily",
        ""
      ],
      [
        "Vitamin K",
        "Hypoprothrombinemia, bone disease (impaired osteoblast function)",
        "2–5 mg i.v. × 3 days",
        "2–5 mg daily",
        "2.5–10 mg daily",
        "5–10 mg oral weekly to daily",
        "Monitor by INR or plasma phylloquinone"
      ]
    ],
    "row_count": 9,
    "column_count": 5
  }
]